UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 174

Sortiert nach

Olaparib for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-05, Vol.382 (22), p.2091-2102

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of DNA damage repair alterations on prostate cancer progression and metastasis

Frontiers in oncology, 2023-06, Vol.13, p.1162644-1162644

2023

Link zum Volltext

Verfügbarkeit prüfen

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply

The New England journal of medicine, 2020-08, Vol.383 (9), p.891-891

2020

Link zum Volltext

Verfügbarkeit prüfen

Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024

European urology, 2021-03, Vol.79 (3), p.e83-e84

2021

Link zum Volltext

Verfügbarkeit prüfen

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-12, Vol.383 (24), p.2345-2357

2020

Link zum Volltext

Verfügbarkeit prüfen

Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon

Journal of general virology, 2008-05, Vol.89 (5), p.1243-1253

2008

Link zum Volltext

Verfügbarkeit prüfen

STAT3 stimulates adipogenic stem cell proliferation and cooperates with HMGA2 during the early stage of differentiation to promote adipogenesis

Biochemical and biophysical research communications, 2017-01, Vol.482 (4), p.1360-1366

2017

Link zum Volltext

Verfügbarkeit prüfen

Hepatocytic AP-1 and STAT3 contribute to chemotaxis in alphanaphthylisothiocyanate-induced cholestatic liver injury

Toxicology letters, 2023-01, Vol.373, p.184-193

2023

Link zum Volltext

Verfügbarkeit prüfen

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Clinical cancer research, 2022-04, Vol.28 (8), p.1518-1530

2022

Link zum Volltext

Verfügbarkeit prüfen

Model-Free Deadbeat Predictive Current Control for SPMSM Based on Adaptive Gain Extended State Observer

IEEE transactions on transportation electrification, 2024-04, p.1-1

2024

Link zum Volltext
IEEE_Xplore

Research on Body Tube Vibration Response of Small Combat Robots Motion

Mathematical problems in engineering, 2023-04, Vol.2023, p.1-14

2023

Link zum Volltext

Verfügbarkeit prüfen

SARS‐CoV‐2 infection negatively impacts on the quality of embryos by delaying early embryonic development

American journal of reproductive immunology (1989), 2024-03, Vol.91 (3), p.e13831-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

The lancet oncology, 2022-10, Vol.23 (10), p.1297-1307

2022

Link zum Volltext

Verfügbarkeit prüfen

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Journal of clinical oncology, 2024-02, Vol.42 (5), p.571

2024

Link zum Volltext

Verfügbarkeit prüfen

Promoter CAG is more efficient than hepatocyte‑targeting TBG for transgene expression via rAAV8 in liver tissues

Molecular medicine reports, 2022-01, Vol.25 (1), Article 16

2022

Link zum Volltext

Verfügbarkeit prüfen

Groundwater vulnerability assessment based on modified DRASTIC model: a case study in Changli County, China

Geocarto international, 2017-07, Vol.32 (7), p.749-758

2017

Link zum Volltext

Verfügbarkeit prüfen

PPARα mediates night neon light-induced weight gain: role of lipid homeostasis

Theranostics, 2020-01, Vol.10 (25), p.11497-11506

2020

Link zum Volltext

Verfügbarkeit prüfen

PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS340-TPS340

2019

Link zum Volltext

Verfügbarkeit prüfen

Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2017-06, Vol.28, p.iii54-iii54

2017

Link zum Volltext

Verfügbarkeit prüfen

Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.126-126

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(159)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(122)
Life Sciences & Biomedicine
(65)
Technology
(42)
Humans
(35)
Physical Sciences
(28)
Engineering
(23)
Male
(21)
Chemistry
(20)
Engineering, Electrical & Electronic
(19)
Animals
(17)
Computer Science
(14)
Female
(13)
Neural Networks
(12)
Mice
(11)
Patients
(11)
Computer Science, Hardware & Architecture
(10)
Middle Aged
(10)
Science & Technology - Other Topics
(10)
Artificial Neural Networks
(9)
Biochemistry & Molecular Biology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Impact of DNA damage repair alterations on prostate cancer progression and metastasis

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon

STAT3 stimulates adipogenic stem cell proliferation and cooperates with HMGA2 during the early stage of differentiation to promote adipogenesis

Hepatocytic AP-1 and STAT3 contribute to chemotaxis in alphanaphthylisothiocyanate-induced cholestatic liver injury

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Model-Free Deadbeat Predictive Current Control for SPMSM Based on Adaptive Gain Extended State Observer

Research on Body Tube Vibration Response of Small Combat Robots Motion

SARS‐CoV‐2 infection negatively impacts on the quality of embryos by delaying early embryonic development

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

Promoter CAG is more efficient than hepatocyte‑targeting TBG for transgene expression via rAAV8 in liver tissues

Groundwater vulnerability assessment based on modified DRASTIC model: a case study in Changli County, China

PPARα mediates night neon light-induced weight gain: role of lipid homeostasis

PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)

Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)

Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound

Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1 , BRCA2 or ATM : Results from the PROfound study

Suchergebnisse filtern